ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2022
Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Empirical therapy versus tailored therapy for Helicobacter pylori infection? A systematic review.BMC infectious diseases · 2025Pooled it
- Minocycline in the eradication ofWorld journal of gastroenterology · 2024Pooled it
- Levofloxacin versus moxifloxacin in nitazoxanide-based quadruple therapy as a first-line treatment for Helicobacter pylori infection: NILE, a randomized, comparative, multicenter study.Scientific reports · 2026Trial
- A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication ofInfection and drug resistance · 2023Trial
- Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicatingFrontiers in immunology · 2022Trial
- From screening to surveillance: integrated prevention ofThe Lancet regional health. Western Pacific · 2026Review
- Economic Evaluation of Empirical and Tailored Helicobacter pylori Eradication Strategies Including Second-Line Therapy.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
- Factors related to loss to follow-up and low compliance in Helicobacter pylori-infected children: The EuroPedHp Registry.Journal of pediatric gastroenterology and nutrition · 2026Observational
- Practice Tips From the UpdatedGastroenterology & hepatology · 2026Article
- OptimizingWorld journal of gastroenterology · 2026Article
- Role of Vonoprazan-Amoxicillin Dual Therapy in Pediatric RefractoryACG case reports journal · 2025Article
- Controversies in management of Helicobacter pylori infection from a U.S. perspective: population screening and treatment.Minerva gastroenterology · 2025Review
- Global Profile of Drug Resistance Related toHealth science reports · 2025Review
- SIMPLE: A One-Pot RPA-Cas12b Method for Single Nucleotide Variations Identification with an Expanded Scope and Clinical Applications.Phenomics (Cham, Switzerland) · 2025Article
- First-Line Prescriptions and Effectiveness ofAntibiotics (Basel, Switzerland) · 2025Article
- Antibiotic Resistance of Helicobacter pylori: Current Trends in Daegu-Kyungpook.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Resistome and virulome determination inMicrobiology spectrum · 2025Article
- Analysis of antibiotic susceptibility and genomic characteristics of Helicobacter pylori by whole-genome resequencing in Northern China.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Recommendations and Adjuvant Therapies to Mitigate Clarithromycin-ResistantInfection and drug resistance · 2025Review
- Amoxicillin or tetracycline in bismuth-containing quadruple therapy forFrontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
We provide a primer to assist in the difficult transition of Helicobacter pylori therapy guidelines to those that adhere to the principles of antimicrobial stewardship. This transition will entail abandonment of many of the principles that heretofore formed the basis of treatment guidelines and recommendations. The goals of antimicrobial stewardship include optimization of the use of antibiotics while reducing antimicrobial resistance. The critical outcome measure is absolute cure rate which largely restricts comparative trials to those which reliably produce high cure rates (eg, ∼95%). Therapies that fail to achieve at least a 90% cure rate should be abandoned as unacceptable. Because only optimized therapies should be prescribed, guidance on the principles and practices of optimization will we required. Therapies that contain antibiotics which do not contribute to outcome should be eliminated. Surveillance, one of the fundamental elements of antimicrobial stewardship, must be done to provide ongoing assurance that the recommended therapies remain effective. It is yet not widely recognized when utilizing otherwise highly successful therapies, the routine test of cure data is an indirect, surrogate method for susceptibility testing. To systematically guide therapy, test of cure data should be collected, shared and integrated into local antimicrobial stewardship programs to provide guidance regarding best practices to both prescribers and public health individuals. Treatment recommendations should be compatible with those of the American Society of Infectious Disease white paper on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens which include criteria for ethical active-controlled superiority studies of antibacterial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.